Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BlackRock Buys $1.3B in Bitcoin and Ethereum

BlackRock Buys $1.3B in Bitcoin and Ethereum

CoinomediaCoinomedia2025/10/08 10:57
By:Ava NakamuraAva Nakamura

BlackRock invests $1.3B in BTC and ETH on Oct 7, adding 7,220 Bitcoin and 93,430 Ethereum to its spot ETFs.What This Means for the MarketA Bullish Sign for Crypto Adoption

  • BlackRock adds over 7,000 BTC worth $899M to its ETFs
  • 93,430 ETH purchased in a single day
  • Institutional interest in crypto continues to rise

In a significant show of confidence in the crypto market , investment giant BlackRock added a staggering $1.3 billion worth of Bitcoin and Ethereum to its spot ETFs on October 7. The purchase included 7,220 BTC , valued at approximately $899.4 million, and 93,430 ETH , worth around $437.5 million.

This marks one of the largest single-day crypto acquisitions by a traditional financial institution, underscoring the increasing role that digital assets play in mainstream finance.

What This Means for the Market

BlackRock’s aggressive purchase signals strong institutional conviction in the long-term value of crypto assets. Bitcoin and Ethereum are the two largest cryptocurrencies by market cap, and their inclusion in BlackRock’s ETFs gives traditional investors easier exposure to digital assets without directly holding them.

Such large-scale investments typically reflect expectations of upward price movement or long-term growth. With macroeconomic uncertainty still looming, many institutions are turning to Bitcoin and Ethereum as alternative stores of value and hedging tools.

🔥 BIG: BlackRock spot ETFs bought 7,220 $BTC worth $899.4M and 93,430 $ETH worth $437.5M on Oct. 7. pic.twitter.com/aqyCbKBygN

— Cointelegraph (@Cointelegraph) October 8, 2025

A Bullish Sign for Crypto Adoption

This move also supports the broader narrative of increasing crypto adoption among legacy financial players. BlackRock’s continued involvement may encourage other institutions to follow suit, boosting overall confidence in the crypto ecosystem.

Moreover, spot ETFs like these bring transparency, regulation , and mainstream acceptance—factors that could accelerate the next bull run.

0
1

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26